登录

Kraig Biocraft Laboratories就市场对最近公司里程碑和股东沟通的反应发表声明

Kraig Biocraft Laboratories Provides a Statement on the Market Response to Recent Company Milestones and Shareholder Communications

BioSpace 2024-05-16 22:21 翻译由动脉网AI生成,点击反馈

可切换为仅中文


Ann Arbor, Michigan--(Newsfile Corp. - May 15, 2024) - Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ('Company'), announces that it remains proud to share information relating to its recent progress and the resounding success of the spring production trials. The Company has been and will continue to be active in its investor awareness program to ensure that our shareholders and the public are updated with our accomplishments and plans for the immediate future..

密歇根州安阿伯市--(新闻文件公司-2024年5月15日)-Kraig Biocraft Laboratories,Inc.(OTCQB:KBLB)(“公司”)宣布,它仍然很自豪地分享有关其最新进展和春季生产试验取得巨大成功的信息。公司一直并将继续积极参与其投资者意识计划,以确保我们的股东和公众了解我们近期的成就和计划。。

At the request of OTC Markets Group, the Company has reviewed its investor relations (IR) program and recent publications to ensure that it is holding its IR program and all vendors to our strict guidelines and expectations. The Company was made aware on May 13 of an editorial on 24/7 Market News highlighting recent advancements in spider silk production and the potential impacts on the market.

应OTC市场集团的要求,该公司已经审查了其投资者关系(IR)计划和最近的出版物,以确保其IR计划和所有供应商遵守我们的严格指导方针和期望。5月13日,该公司获悉一篇关于全天候市场新闻的社论,重点介绍了蜘蛛丝生产的最新进展以及对市场的潜在影响。

This publication was drafted by a third-party contractor hired by the Company's IR team and included a full disclosure of financial compensation as required. While the Company did not have editorial control over the recent publication on 24/7 Market News, the documents that we have reviewed, in our opinion, are truthful and factual..

本出版物由该公司IR团队聘请的第三方承包商起草,并根据要求全面披露了财务补偿。虽然该公司对最近24/7市场新闻的发布没有编辑控制权,但我们认为我们审查的文件是真实的。。

Our policy requires our IR providers to fully and completely disclose any compensation they receive and that all information is factual, or if an honestly held opinion, is stated as an opinion. Beyond the strict legal compliance our IR providers maintain, we have recently requested that they eliminate suggestions about how our operational breakthroughs may impact market responses..

我们的政策要求我们的IR提供商充分、完整地披露他们收到的任何赔偿,并且所有信息都是真实的,或者如果诚实持有的意见被陈述为意见。除了我们的IR提供商保持严格的法律合规性之外,我们最近还要求他们消除关于我们的运营突破如何影响市场反应的建议。。

Kraig Labs has long-standing and productive working relationships with Hansel Capital and Karolus Maximus Kapital. These two firms provide the Company with support for shareholder inquiries and investor relations services. The Company has hired and directed these two supporting firms to create and provide shareholders and the public with updates and news on the Company's progress.

Kraig实验室与Hansel Capital和Karolus Maximus Kapital有着长期而富有成效的工作关系。这两家公司为公司提供股东咨询和投资者关系服务的支持。该公司聘请并指导这两家支持公司创建并向股东和公众提供公司进展的最新信息和新闻。

We are very aware of the added burden our strict compliance policies place on these contractors and thank them for their work and efforts..

我们非常清楚我们严格的合规政策给这些承包商带来的额外负担,并感谢他们的工作和努力。。

With a series of production breakthroughs in the first quarter and early second quarter of 2024, the Company has significantly increased communication efforts to share these successes with its shareholders and the markets. The Company remains committed to delivering its vision of metric-ton scale manufacturing of spider silk..

随着2024年第一季度和第二季度初的一系列生产突破,该公司大大增加了沟通力度,以与股东和市场分享这些成功。该公司仍致力于实现其蜘蛛丝公吨规模生产的愿景。。

As an SEC-compliant, fully reporting public Company, we hold the highest standards for reporting and public disclosure. No Company officers, insiders, control persons, or contracted third-party providers have traded in the Company's common stock over the last 90 days. No shares of the Company's common stock have been issued to any party in the last 90 days.

作为一家符合美国证券交易委员会(SEC)要求、全面报告的上市公司,我们拥有最高的报告和公开披露标准。在过去90天内,没有公司管理人员、内部人士、控制人员或签约的第三方提供商交易过公司的普通股。在过去90天内,公司普通股未向任何一方发行。

The Company's CEO did acquire one restricted non-tradable preferred share in April 2024. As a part of its reporting requirements, all stock sales, convertible instruments, registered offerings, or private placements have been reported in our public filings found on the Company's website or through the SEC EDGAR system..

该公司首席执行官于2024年4月收购了一股限制性非流通优先股。作为其报告要求的一部分,所有股票销售、可转换工具、注册发行或私募均已在公司网站或SEC EDGAR系统上的公开文件中报告。。

Our shareholders can expect us to continue to work diligently to improve our fundamentals and share the Company's progress through all available and appropriate channels.

我们的股东可以期望我们继续努力改善我们的基本面,并通过所有可用和适当的渠道分享公司的进步。

Our recent announcements regarding the success of the spring production trials were a major milestone for the Company and represent a strong shift to scaled production. The Company believes that the improvements in our fundamentals and spreading of the word of these positive changes, including our advancements in production through our website, press release, and investor relations providers, have significantly impacted our market dynamics.

我们最近宣布的春季试产成功是该公司的一个重要里程碑,代表着向规模化生产的有力转变。该公司认为,我们基本面的改进和这些积极变化的传播,包括我们通过网站、新闻稿和投资者关系提供商在生产方面的进步,对我们的市场动态产生了重大影响。

This is an exciting time for Kraig Labs, and we believe there is a bright future for the Company and recombinant spider silk..

这对Kraig实验室来说是一个激动人心的时刻,我们相信该公司和重组蜘蛛丝有着光明的未来。。

To view the most recent edition of Kraig's Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter

要查看Kraig最新版本的蜘蛛感应季度通讯和/或注册公司警报,请访问www。KraigLabs.com/newsletter

About Kraig Biocraft Laboratories, Inc.

关于Kraig Biocraft Laboratories,Inc。

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

Kraig Biocraft Laboratories,Inc.(www.KraigLabs.com)是一家报告生物技术公司,是基因工程蜘蛛丝基纤维技术的领先开发商。

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

该公司在蜘蛛丝技术领域取得了一系列科学突破,对全球纺织业产生了影响。

Cautionary Statement Regarding Forward Looking Information

关于前瞻性信息的警示声明

Statements in this press release about the Company's future and expectations other than historical facts are 'forward-looking statements.' These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass.

本新闻稿中关于公司未来和预期(而非历史事实)的声明是“前瞻性声明”这些声明是根据管理层当前的观点和假设做出的。因此,无法保证管理层的期望一定会实现。

These forward-looking statements generally can be identified by phrases such as 'believes,' 'plans,' 'expects,' 'anticipates,' 'foresees,' 'estimated,' 'hopes,' 'if,' 'develops,' 'researching,' 'research,' 'pilot,' 'potential,' 'could' or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals.

这些前瞻性陈述通常可以通过诸如“相信”、“计划”、“期望”、“预期”、“预见”、“估计”、“希望”、“如果”、“发展”、“研究”、“研究”、“试点”、“潜力”、“可能”或其他类似含义的单词或短语来识别。前瞻性陈述包括对公司业务战略、前景、目标、计划、意图和目标的描述。

All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security..

所有此类前瞻性陈述都受到某些风险和不确定性的影响,这些风险和不确定性可能导致实际结果与前瞻性陈述中的结果存在重大差异。本新闻稿不构成出售要约或购买任何证券的要约。。

Ben Hansel, Hansel Capital, LLC

我是Hansel,Hansel Capital,LLC

(720) 288-8495

(720) 288-8495

ir@KraigLabs.com

ir@KraigLabs.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/209329

要查看此新闻稿的源版本,请访问https://www.newsfilecorp.com/release/209329

推荐阅读

J Ethnopharmacol:局部应用青蒿精油可改善DNCB致小鼠特应性皮炎

MedSci 2024-06-16 09:27

European Radiology:MRI信号强度标准化对基于放射组学预测分子胶质瘤亚型的影响

MedSci 2024-06-16 08:36

European Radiology:18F-FDG和68Ga-FAPI PET/CT对胸部原发性肺外肿瘤的评价比较

MedSci 2024-06-16 08:34

BioSpace

3176篇

最近内容 查看更多

全球2b期临床试验数据在EULAR 2024上的口头陈述证明了单次注射MM-II对疼痛性膝骨关节炎(OA)患者疼痛缓解的持久性

1 天前

Cantargia报告了正在进行的CAN10 1期临床试验的进一步进展

1 天前

Greenwich LifeSciences宣布250万美元私募

1 天前

产业链接查看更多